nine compounds were identified as vanillic (14 mg, 3), syringic (18 mg, 4), cinnamic (24 mg, 5) [20], p-coumaric (11 mg, 6),
o-coumaric (5 mg, 7) [21], ferulic (14 mg, 8), and isoferulic acids (8 mg, 9) [22]; quercetin (9 mg, 10), and isorhamnetin
(16 mg, 11) [23]. Fractions F-3 (12 g) and F-4 (60 g) were separated by CC over polyamide (4 ꢆ 100 cm, H O–EtOH eluent,
2
100:0ꢇ96:4), SiO (3 ꢆ 60 cm, C H –EtOAc eluent, 100:0ꢇ70:30; EtOAc–EtOH, 100:0ꢇ70:30), Sephadex LH-20
2
6 14
(3 ꢆ 70 cm, EtOH–H O eluent, 96:4ꢇ0:100), RP-SiO (2 ꢆ 50 cm, H O–MeCN eluent, 100:0ꢇ0:100), and preparative TLC
2
2
2
on SiO (toluene–EtOAc–HCOOH, 5:4:1). This resulted in the isolation of 29 compounds including from fraction F-3
2
isorhamnetin-3-O-(2ꢀ-acetyl-)-ꢁ-D-glucopyranoside (18 mg, 1), isorhamnetin-3-O-(2ꢀ,6ꢀ-diacetyl-)-ꢁ-D-glucopyranoside
(12 mg, 2); caffeic acid (27 mg, 12) [21]; 3-O- (68 mg, 13), 5-O- (24 mg, 14), 1,3-di-O- (11 mg, 15), 3,4-di-O- (18 mg, 16),
3,5-di-O- (33 mg, 17), 4,5-di-O- (14 mg, 18), 1,3,5-tri-O- (20 mg, 19), and 3,4,5-tri-O-caffeylquinic acids (7 mg, 20);
5-O-ferulylquinic acid (5 mg, 21) [24], quercitrin (18 mg, 22), isoquercitrin (35 mg, 23) [25], quercetin-3-O-(2ꢀ-acetyl-)-ꢁ-D-
glucopyranoside (12 mg, 24), quercetin-3-O-(6ꢀ-acetyl)-ꢁ-D-glucopyranoside (14 mg, 25), quercetin-3-O-(2ꢀ,6ꢀ-diacetyl)-ꢁ-
D-glucopyranoside (4 mg, 26) [26], isorhamnetin-3-O-ꢁ-D-glucopyranoside (31 mg, 27) [25], isorhamnetin-3-O-ꢅ-L-
rhamnopyranoside (5 mg, 28), calendoflaside [isorhamnetin-3-O-(2ꢀ-ꢅ-L-rhamnopyranosyl)-ꢅ-L-rhamnopyranoside] (37 mg,
29) [9], and isorhamnetin-3-O-(6ꢀ-acetyl)-ꢁ-D-glucopyranoside (16 mg, 30) [6]. Fraction F-4 afforded 4-O-caffeylquinic
acid (12 mg, 31) [24], quercetin-3-O-(2ꢀ-ꢅ-L-rhamnopyranosyl)-ꢅ-L-rhamnopyranoside (32 mg, 32) [10], rutin (212 mg, 33),
narcissin [isorhamnetin-3-O-(6ꢀ-ꢅ-L-rhamnopyranosyl)-ꢁ-D-glucopyranoside] (3.25 g, 34) [25], calendoflavoside
[isorhamnetin-3-O-(2ꢀ-ꢅ-L-rhamnopyranosyl)-ꢁ-D-glucopyranoside] (52 mg, 35), calendoflavobioside [quercetin-3-O-
(2ꢀ-ꢅ-L-rhamnopyranosyl)-ꢁ-D-glucopyranoside] (107 mg, 36) [9], manghaslin [quercetin-3-O-(2ꢀ,6ꢀ-di-ꢅ-L-
rhamnopyranosyl)-ꢁ-D-glucopyranoside] (114 mg, 37) [27], and typhaneoside [isorhamnetin-3-O-(2ꢀ,6ꢀ-di-ꢅ-L-
rhamnopyranosyl)-ꢁ-D-glucopyranoside] (2.28 g, 38) [10]. Fraction F-5 (50 g) was placed on Amberlite XAD7HP (300 g)
and eluted with H O and EtOH (50%). The EtOH eluate was concentrated and chromatographed over RP-SiO (2 ꢆ 50 cm,
2
2
H O–MeCN eluent, 100:0ꢇ0:100) to isolate the three compounds 1-O-caffeylglucose (14 mg, 39), 1-O-caffeylquinic acid
2
(21 mg, 40), and 3-O-p-coumarylquinic acid (9 mg, 41) [24].
+
Isorhamnetin-3-O-(2ꢀ-acetyl-)-ꢁ-D-glucopyranoside (1). C H O . HR-ESI-MS m/z: 543.421 ([M + Na] ;
24 24 13
+
+
calcd 543.441). + FAB-ÌS m/z: 521 [M + H] , 317 [(M – Glc – acetate) + H] . UV spectrum (ÌåÎÍ, ꢈ , nm): 256, 266 sh,
max
359; + AlCl 270, 306, 405; + AlCl /HCl 270, 305, 406; + NaOAc 275, 321, 389; + NaOAc/H BO 257, 266 sh, 360;
3
3
3
3
–1
1
13
+ NaOMe 272, 332, 418. IR spectrum (ꢉ , cm ): 1725, 1652 (ꢉ ). Í NMR (500 MHz, ÌåÎÍ-d , ꢃ, ppm) and Ñ NMR
max
ÑÎ
4
(125 MHz, ÌåÎÍ-d , ꢃ, ppm), see Table 2.
Isorhamnetin-3-O-(2ꢀ,6ꢀ-diacetyl-)-ꢁ-D-glucopyranoside (2). C H O . HR-ESI-MS m/z: 585.263 ([M + Na] ;
calcd 585.479). + FAB-ÌS m/z: 563 [M + H] , 317 [{M – Glc – (2 ꢆ acetate)} + H] . UV spectrum (ÌåÎÍ, ꢈ , nm): 256,
4
+
26 26 14
+
+
max
265 sh, 359; + AlCl 270, 305, 405; + AlCl /HCl 271, 305, 406; + NaOAc 275, 322, 390; + NaOAc/H BO 257, 266 sh, 360;
3
3
3
3
–1
1
13
+ NaOMe 272, 332, 419. IR spectrum (ꢉ , cm ): 1724, 1652 (ꢉ ). Í NMR and Ñ NMR, see Table 2.
max
ÑÎ
+
Isorhamnetin-3-O-(6ꢀ-acetyl-)-ꢁ-D-glucopyranoside (30). C H O . HR-ESI-MS m/z: 543.421 ([M + Na] ;
27 30 16
+
+
calcd 543.441). + FAB-ÌS m/z: 521 [M + H] , 317 [(M – Glc – acetate) + H] . UV spectrum (ÌåÎÍ, ꢈ , nm): 255, 266 sh,
max
360; + AlCl 270, 306, 405; + AlCl /HCl 270, 304, 406; + NaOAc 275, 321, 389; + NaOAc/H BO 257, 266 sh, 361;
3
3
3
3
–1
1
+ NaOMe 272, 332, 420. IR spectrum (ꢉ , cm ): 1722, 1650 (ꢉ ). Í NMR (500 MHz, ÌåÎÍ-d , ꢃ, ppm, J/Hz): 1.64
max
ÑÎ
4
(3Í, s, Glc 6ꢂꢂ-COÑÍ ), 3.11–3.36 (4Í, m, Glc H-2ꢂꢂ-5ꢂꢂ), 3.81 (3Í, s, 3ꢂ-ÎÑÍ ), 4.05 (1Í, m, Glc H-6ꢂꢂ ), 4.21 (1Í, dd,
3
3
B
J = 2.0, 12.0, Glc H-6ꢂꢂ ), 5.81 (1Í, d, J = 7.7, Glc H-1ꢂꢂ), 6.14 (1Í, d, J = 2.2, Í-6), 6.33 (1Í, d, J = 2.2, Í-8), 6.89 (1Í, d,
À
13
J = 9.0, Í-5ꢂ), 7.44 (1Í, dd, J = 9.0, 1.8, Í-6ꢂ), 7.85 (1Í, d, J = 2.0, Í-2ꢂ). Ñ NMR (125 MHz, ÌåÎÍ-d , ꢃ, ppm): 20.1
4
(C, 6ꢂꢂ-ÎÑÑÍ ), 55.1 (CH , 3ꢂ-ÎÑÍ ), 63.7 (CH , Glc C-6ꢂꢂ), 70.1 (CH, Glc C-4ꢂꢂ), 73.3 (CH, Glc C-2ꢂꢂ), 76.6 (CH,
3
3
3
2
Glc C-5ꢂꢂ), 77.7 (CH, Glc C-3ꢂꢂ), 93.4 (CH, C-8), 100.0 (CH, C-6), 101.4 (CH, Glc C-1ꢂꢂ), 104.2 (C, C-10), 112.7 (CH, C-2ꢂ),
115.8 (CH, C-5ꢂ), 121.5 (C, C-1ꢂ), 122.6 (CH, C-6ꢂ), 133.8 (C, C-3), 146.3 (C, C-4ꢂ), 149.1 (C, C-3ꢂ), 156.2 (C, C-9), 156.3
(C, C-2), 161.1 (C, C-5), 164.3 (C, C-7), 170.9 (CH , 6ꢂꢂ-ÎÑÑÍ ), 178.2 (C, C-4).
3
3
Total Hydrolysis of 1 and 2. The compound (2 mg) was dissolved in TFA (5 mL, 5%) in Me CO and heated at
2
100°C (2 h). The hydrolysate was concentrated in vacuo, dissolved in MeOH, and analyzed by HPLC. The presence of
isorhamnetin (t 11.21 min, conditions 1) and glucose (t 14.14 min, conditions 2) was established.
R
R
Alkaline Hydrolysis of 1 and 2. The compound (2 mg) was dissolved in NaOH solution (1 mL, 0.4%) and heated
at 50°C (30 min). The hydrolysate was neutralized with HCl (0.4%) and placed on a RP-SiO Diapak C16M cartridge
2
(BioKhimMak) that was eluted with H O and EtOH (70%). Analysis of the resulting eluates by HPLC found isorhamnetin-3-
2
O-ꢁ-D-glucopyranoside in the EtOH eluate (t 6.98 min, conditions 1) and acetate in the H O eluate (t 18.24 min,
R
2
R
conditions 3).
838